ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Nonsteroidal antiinflammatory drugs (NSAIDs)"

  • Abstract Number: 1646 • ACR Convergence 2022

    Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs Initiation in Patients with Rheumatoid Arthritis

    Gulsen Ozen1, Sofia Pedro2 and Kaleb Michaud3, 1University of Nebraska Medical Center, Bellevue, NE, 2Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 3University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Pain management is challenging in RA where ~60% of patients with well-controlled disease activity still experience bothersome pain. The opioid epidemic in the US…
  • Abstract Number: 1673 • ACR Convergence 2022

    Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort

    SABRINA HAMROUN1, Marion Couderc2, Rene-Marc Flipo3, Jérémie SELLAM4, Christophe Richez5, Emmanuelle Dernis6, Aline Frazier-Mironer7, Laure Gossec8, elisabeth gervais9, Hubert Marotte10, Laetitia Dunogeant11, Cédric Lukas12, Alban DEROUX13, Nathalie Costedoat-Chalumeau14 and Anna Molto15, 1Rheumatology Department, University Hospital of Cochin, Paris, Paris, France, 2University Hospital, Clermont-Ferrand, France, 3CHU Lille, Boulogne-Billancourt, France, 4Sorbonne Universite, AP-HP, Saint-Antoine hospital, Paris, France, 5Université de Bordeaux, Bordeaux, France, 6LE MANS general hospital, LE MANS, France, 7APHP Hôpital Lariboisire, Paris, France, 8Sorbonne Université, Paris, France, 9chu poitiers, Poitiers, France, 10INSERM 1059, Saint-Etienne, France, 11Hospital of Aix en Provence, Marseille, France, 12University Hospital Centre Montpellier, University of Montpellier, Montpellier, France, 13CHU Grenoble, Grenoble, France, 14Inserm DR Paris 5, Paris, France, 15Rheumatology Department, Cochin Hospital, APHP, Paris, France

    Background/Purpose: Spondyloarthritis (SpA) is one of the most common chronic inflammatory diseases and regularly affects women of childbearing age. However, there is limited knowledge about…
  • Abstract Number: 1794 • ACR Convergence 2022

    Characteristics of Patients with Repeat Visits for Acute Gout at a University Hospital Emergency Department

    David Lim1, Manushi Aggarwal1 and Marven Cabling2, 1Loma Linda University Health, Redlands, CA, 2Loma Linda University, REDLANDS, CA

    Background/Purpose: Gout is the most common inflammatory arthritis in adults that results in high disease burden and health care utilization. The objective of the study…
  • Abstract Number: 1809 • ACR Convergence 2022

    Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial

    Keigo Hayashi1, yuqing zhang2, Hyon Choi3 and Kazuki Yoshida4, 1Brigham and Women's Hospital, Okayama, Japan, 2Massachusetts General Hospital, Quincy, MA, 3MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, 4Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…
  • Abstract Number: PP25 • ACR Convergence 2022

    From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective

    Shung Chiu1 and Mei Nee Chiu2, 1Spondylitis Association of America, Ludhiana, Punjab, India, 2University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India

    Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
  • Abstract Number: 0073 • ACR Convergence 2022

    Opioid and Pain Medication Prescribing by Rheumatologists for Medicare Part D Beneficiaries from 2013 to 2019

    Erin Valley1, Connor Pedersen1, Kathryn Henry2, Ali Duarte-Garcia3, Viktoriya Sabchyshyn1 and Mike Putman4, 1Medical College of Wisconsin, Milwaukee, WI, 2Medical College of Wisconsin, Manitowoc, WI, 3Mayo Clinic, Rochester, MN, 4The Medical College of Wisconsin, Milwaukee, WI

    Background/Purpose: Prescription opioid medications are highly effective in managing acute pain, but their use for chronic pain remains controversial. The objective of this study is…
  • Abstract Number: 0420 • ACR Convergence 2022

    What Does It Mean – A Good Response to NSAIDs? A Systematic Comparison of Patients with Axial Spondyloarthritis and Controls with Chronic Back Pain

    Xenofon Baraliakos1, Imke Redeker2, Elena Bergmann3, Styliani Tsiami4 and Juergen Braun5, 1Rheumazentrum Ruhrgebiet Herne, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Bochum, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, 5Rheumazentrum Ruhrgebiet, Herne, Germany

    Background/Purpose: A fast response to NSAIDs is an important finding in the evaluation of clinical findings within the items comprising the ASAS classification criteria but…
  • Abstract Number: 0546 • ACR Convergence 2022

    COmparison of the Effect of Treatment with NSAIDs Added to Anti-TNF Therapy versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine over Two Years in Patients with Ankylosing Spondylitis (CONSUL): An Open-Label, Randomized Controlled, Multicenter Trial

    Fabian Proft1, Bukrhard Muche2, valeria Rios-Rodriguez3, Murat Torgutalp4, Mikhail Protopopov5, Joachim Listing6, Maryna Verba7, Jan Brandt-Juergens8, Uta Kiltz9, Maren Sieburg10, Swen Jacki11, Joachim Sieper4 and Denis Poddubnyy1, 1Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Charité University Hospital, CCM, Berlin, Germany, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Charité - Universitätsmedizin, Berlin, Berlin, Germany, 5Charité Universitätsmedizin Berlin, Berlin, Germany, 6German Rheumatism Research Centre, Epidemiology Unit, Berlin, Germany, 7Charité – Universitätsmedizin Berlin, Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, 8Rheumatologische Schwerpunktpraxis, Berlin, Germany, 9Rheumazentrum Ruhrgebiet, Herne, Germany, 10Rheumatologische Facharztpraxis, Magdeburg, Germany, 11Rheumatologische Schwerpunktpraxis, Tübingen, Germany

    Background/Purpose: There is some evidence that NSAIDs, in particular celecoxib (CEL), might possess not only symptomatic efficacy but also disease-modifying properties in ankylosing spondylitis (AS),…
  • Abstract Number: 0058 • ACR Convergence 2021

    Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model

    Sophie Hecquet1, Perle Totoson2, Maude Tournier2, Clement Prati1, Daniel Wendling1, Céline Demougeot2 and Frank Verhoeven1, 1Service de rhumatologie, CHU de Besançon, Besançon, France, 2PEPITE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France

    Background/Purpose: The intestine is no longer considered as an organ targeted by spondyloarthritis (SpA) but also an actor of the disease alongside environmental and immunological…
  • Abstract Number: 0483 • ACR Convergence 2021

    Frequent Use of Prescription Oral NSAIDs Among People with Knee or Hip Osteoarthritis Despite Contraindications to or Precautions with NSAIDs

    Tuhina Neogi1, Andrea Dell'isola2, Martin Englund2 and Aleksandra Turkiewicz2, 1Boston University School of Medicine, Boston, MA, 2Lund University, Lund, Sweden

    Background/Purpose: Oral NSAIDs are recommended for OA management. However, many patients with OA have contraindications to NSAIDs or have comorbidities that warrant precaution. Because few…
  • Abstract Number: 0728 • ACR Convergence 2021

    Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study

    Philip Conaghan1, Xavier Chevalier2, Linda Mindeholm3, Ursula Schramm3, Jens Praestgaard3, Abdelkader Seroutou3, Ronenn Roubenoff3 and Matthias Schieker3, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, 3Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland

    Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
  • Abstract Number: 0908 • ACR Convergence 2021

    Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Secukinumab in Patients with Ankylosing Spondylitis: Multicenter, Randomised, Double-blind, Phase IV Study

    Uta Kiltz1, Xenofon Baraliakos1, Jan Brandt-Jrgens2, Ulf Wagner3, Sebastian Lieb4, Christian Sieder5, Christian Mann5 and Jürgen Braun1, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, 2Rheumatologische Schwerpunktpraxis, Berlin, Germany, 3Universitätsklinikum Leipzig, Leipzig, Germany, 4Novartis Pharma GmbH, Immunology, Hepatology and Dermatology, Nürnberg, Germany, 5Novartis Pharma GmbH, Nürnberg, Germany

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used to treat inflammatory back pain in patients (pts) with ankylosing spondylitis (AS). However, an increased risk of side…
  • Abstract Number: 0924 • ACR Convergence 2021

    Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension

    Désirée van der Heijde1, Atul Deodhar2, Walter Maksymowych3, Joachim Sieper4, Filip Van den Bosch5, Tae-Hwan Kim6, Mitsumasa Kishimoto7, Andrew Ostor8, Bernard Combe9, Yunxia Sui10, Yuanyuan Duan11, Alvina D. Chu11 and In-Ho Song12, 1Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 2Oregon Health & Science University, Portland, OR, 3Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, 4Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 5Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, 6Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, 9Montpellier University, Montpellier, France, 10AbbVie, North Chicago, IL, 11AbbVie Inc, North Chicago, 12AbbVie Inc., North Chicago, IL

    Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
  • Abstract Number: 0939 • ACR Convergence 2021

    Non-steroidal Anti-inflammatory Drug Use Is Associated with Disease Activity and Reduced Significantly in Patients with Axial Spondyloarthritis Treated with Tumor Necrosis Factor Inhibitors; Data from a Real Life Experience

    Elif Ediboglu1, Dilek Solmaz2, Gokhan Kabadayi3, eda otman1, Haluk Cinaklı1, Gulay Alp1, Esra Erpek1, Sercan Gücenmez4, Mustafa Ozmen4 and Servet Akar2, 1Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, 2Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, 3Cigli Education and Research Hospital, İzmir, Turkey, 4katip çelebi university, izmir, Turkey

    Background/Purpose: Bacground: Non-steroidal anti-inflammatory drugs (NSAIDs) is the first line treatment option in axial spondyloarthritis (axSpA) patients suffering from pain and stiffness. However there is…
  • Abstract Number: 1447 • ACR Convergence 2021

    Long-Term Effect of Prescription Non-Steroidal Anti-Inflammatory Drug Regular Use on the Risk of a Knee Replacement

    S. Reza Jafarzadeh1, Tuhina Neogi1 and David Felson2, 1Boston University School of Medicine, Boston, MA, 2Boston University, Boston, MA

    Background/Purpose: Non-steroidal anti-inflammatory drugs (NSAIDs) are a primary treatment for osteoarthritis (OA). It is uncertain, however, whether regular use of NSAIDs affects the risk of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology